Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

urial. The model will also promote a new culture open to external collaboration. In line with this approach, a number of alliances were agreed during the period, while existing alliances bore fruit. Excellent Phase II results from the recently-acquired product BSI-201 in triple negative breast cancer were presented to the American Society of Clinical Oncology (ASCO), and the product has since moved into Phase III. A license agreement has been signed with Exelixis, along with an exclusive research collaboration to discover PI3K inhibitors in the treatment of malignant tumors. We have also entered into a collaboration agreement with Kyowa Kirin.
  • Exploring external growth opportunities - In July, our Vaccines business in emerging markets received a significant boost with the acquisition of Shanta Biotechnics in India. This acquisition follows on from those of Zentiva, Kendrick, Medley and BiPar Sciences, Inc. earlier in the year.
  • Adapting our structures to meet the challenges of the future - Implementation of this program is intended to improve the efficiency of our operations, with a target of euro 2 billion of recurring cost savings(6) in 2013 relative to 2008. These savings will be achieved across all Group functions.
  • Our aim is therefore to achieve at least the same level of sales in 2013 vs. 2008 before any significant external growth opportunities. Key growth drivers (Vaccines, Diabetes products, Emerging markets, OTC / OTX, Japan, New launches) aim at largely mitigating the impact on sales of upcoming patent expiries and also providing more sustainable growth with a reduced risk profile as of 2013.

    Our target efficiency savings of 2 billion euros and the contribution of existing key growth drivers aim at offsetting the impact of genericization and achieving a comparable net income level in 2013 vs. 2008. Furthermore, our strong financial position sho
    '/>"/>

    SOURCE sanofi-aventis
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

    Related biology technology :

    1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
    2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
    3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
    4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
    5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
    6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
    7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
    8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
    9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
    10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
    (Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
    (Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
    (Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
    Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
    ... 20 Cardium Therapeutics (NYSE Amex: CXM ... and Chief Executive Officer will present at the 10th ... September 29-30, 2010 at the Radisson Blu Hotel in ... can access a replay of the Company,s recent presentation ...
    ... ... if (typeof(lpUnit)==,undefined,) var ... var shortURL = ""; BitlyCB.alertResponse = function(data) ... grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var ...
    ... energy could be a central alternative to petroleum-based energy ... the same energy yield and is more expensive to ... solar energy production on the environment is incomplete, experts ... benefits and detriments of solar power, a research team ...
    Cached Biology Technology:Cardium to Present at 10th Annual Biotech in Europe Investor Forum 2China-Biotics Hosted its First Investor Day Event 2China-Biotics Hosted its First Investor Day Event 3China-Biotics Hosted its First Investor Day Event 4China-Biotics Hosted its First Investor Day Event 5China-Biotics Hosted its First Investor Day Event 6China-Biotics Hosted its First Investor Day Event 7China-Biotics Hosted its First Investor Day Event 8Research team assesses environmental impact of organic solar cells 2
    (Date:4/17/2014)... one per eight hundred births, Down syndrome - or ... of intellectual disability. It results from a chromosomal abnormality ... of chromosome 21 (1% of the human genome). A ... the Department of Genetic Medicine and Development at the ... Nature , shed light on how the extra ...
    (Date:4/17/2014)... House honored Clemson professor Rajendra Singh Thursday as ... promote and expand solar deployment in the residential, ... Houser Banks Professor of Electrical and Computer Engineering ... is considered a local hero leading the charge ... opportunity in solar power and driving policy changes ...
    (Date:4/17/2014)... are implicated in many serious conditions such as heart ... target for drug therapies. Unfortunately, there is still much ... research provides fresh and unexpected insight into the structure ... - β-subunit molecules - which are responsible for ,fine-tuning, ... in the most recent edition of the Journal ...
    Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2Structure of sodium channels different than previously believed 2
    ... Sept. 16, 2008 Researchers at UT Southwestern ... electrical stimulation of nerves by outfitting electrodes with ... of basic black, formed from carbon nanotubes. ... transmitted by electrodes, which researchers say is a ...
    ... CORVALLIS, Ore. More than 125 years ago Charles Darwin ... the night, not the day and this week, scientists ... phenomenon. These rhythmic growth spurts, and the ability of ... by genes involved in circadian rhythms the "biological clock" ...
    ... Scientists have discovered that certain fish are capable of ... includes striking images of fish fluorescing vivid red ... sunlight by sea-water, objects which look red under normal ... This has contributed to the belief among marine biologists ...
    Cached Biology News:Coating improves electrical stimulation therapy used for Parkinson's, depression, chronic pain 2'Biological clock' genes control plant growth 2
    ...
    ... member of Wyatt Technology's family of light ... your high temperature chromatograph and enables you ... thermoplastic polymers. The HTmD is easily installed ... PL220C or Alliance 2000 device and enables ...
    ...
    ... 3-(3,5-Dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide White solid. PROTECT ... A cell-permeable sulfanamido-benzbromarone compound that acts ... allosteric inhibitor of PTP1B (IC 50 ... μM for PTP1B 403 and ...
    Biology Products: